Trial Profile
A Randomized, Open-Label, Multi-Center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-Operative Therapy in Patients With High Risk Localized Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Epirubicin (Primary) ; Larotaxel (Primary) ; Trastuzumab (Primary) ; Docetaxel
- Indications Adenocarcinoma; Breast cancer
- Focus Therapeutic Use
- Acronyms SATIN
- Sponsors Sanofi
- 09 Dec 2010 Actual end date changed from Mar 2010 to Aug 2010 as reported by ClinicalTrials.gov.
- 22 Nov 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 22 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.